Pharma RSS Digest - 2026-07-15

Overview

Today's pharma tape is anchored by clinical and regulatory catalysts rather than broad market-moving news. Castle Biosciences secured a state-level approval that completes its dermatology footprint in New York, the only U.S. state with formal pre-market review of laboratory-developed tests. In oncology, Kelun-Biotech's Phase III trial of a TROP2 antibody-drug conjugate combined with pembrolizumab hit its primary progression-free survival endpoint in PD-L1-negative non-small cell lung cancer — a historically difficult-to-treat population. Lynk Pharmaceuticals closed enrollment in a Phase III study of an oral JAK1 inhibitor for ankylosing spondylitis. Beyond these, two notable regulatory items — a high-severity device recall and an Alzheimer's subcutaneous dosing approval — shaped the secondary headlines, while labor-market reporting offered narrative texture without substantive numbers.

Key Developments

Castle Biosciences received New York State Department of Health approval for its AdvanceAD-Tx test, a molecular assay designed to guide systemic therapy selection in patients aged 12 and older with moderate-to-severe atopic dermatitis. The test stratifies patients into a JAK inhibitor responder profile or a Th2 molecular profile, with sample collection via a non-invasive lesional skin scraping rather than biopsy. Why it matters: New York is the only state requiring formal pre-market review of laboratory-developed tests, so this approval functions as a regulatory benchmark that effectively unlocks the company's full dermatology and ophthalmology menu in the country's most rigorous diagnostics market. Watch next: pricing and reimbursement details, commercial launch cadence in New York, and any independent validation data underlying the assay.

Castle Biosciences fda approval update

Kelun-Biotech's Phase III OptiTROP-Lung06 trial met its primary PFS endpoint at a prespecified interim analysis, evaluating its TROP2-directed antibody-drug conjugate sac-TMT in combination with pembrolizumab versus pembrolizumab plus pemetrexed/platinum chemotherapy as first-line treatment for PD-L1-negative non-squamous non-small cell lung cancer. The combination also showed a positive overall survival trend with safety consistent with prior reports. Why it matters: PD-L1-negative NSCLC has long been a therapeutic bottleneck where immunotherapy-plus-chemotherapy offers limited durability, and this readout — described as the first Phase III ADC-plus-checkpoint combination to hit its primary endpoint in this population — strengthens both Kelun's domestic positioning and MSD/Merck's global oncology pipeline via their ex-Greater China rights to sac-TMT. Combined with the previously reported PD-L1-positive trial, a positive regulatory path could cover the full first-line driver gene-negative non-squamous population. Watch next: full PFS hazard ratio and OS data, NMPA filing plans, and MSD's potential global filing strategy.

Kelun-Biotech clinical trial update

Lynk Pharmaceuticals completed Phase III enrollment of 352 patients in its trial of zemprocitinib — a second-generation selective JAK1 inhibitor positioned as a potential best-in-class oral therapy for active ankylosing spondylitis. The randomized, placebo-controlled study's primary endpoint is ASAS40 response at Week 16. Why it matters: a successful oral therapy could challenge the biologics-dominated ankylosing spondylitis paradigm and, given zemprocitinib's prior positive Phase III data in rheumatoid arthritis and atopic dermatitis with placebo-comparable serious adverse event rates, support broader platform validation for Lynk's JAK-STAT/inflammation pipeline. Watch next: topline efficacy and safety data, regulatory submission timing, and any read-through to competitive positioning against existing JAK inhibitors and biologics.

Lynk Pharmaceuticals clinical trial update

Watchlist

• Medtronic Harmony Delivery Catheter System recall: A Class I recall — the FDA's most serious designation — targets certain lots of the delivery device (not the implanted valve) over distal tip detachment risk, though no serious injuries or deaths were reported as of mid-May. [link]
• FDA approval of a subcutaneous starting dose for Leqembi: Enables at-home initiation of Alzheimer's treatment via a roughly 15-second weekly autoinjector, replacing prior long IV infusion periods and framed by advocates as infrastructure for future combination regimens. [link]
• BioSpace Q2 2026 Biopharma Job Market Report: Released with a partner recruiting firm; teaser copy references rising job postings and sustained R&D hiring, but the publicly available page carries no figures — quantitative claims require the gated download. [link]